(Q46911236)

English

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

scientific article published on 13 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Désirée van der Heijde

6

object named as

Désirée van der Heijde

0 references

Robert Landewé

9

object named as

Robert Landewé

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

5

object named as

Paul Emery

0 references

Paul Wordsworth

10

object named as

Paul Wordsworth

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

author name string

Dominique Baeten

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Xenofon Baraliakos

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Jürgen Braun

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Joachim Sieper

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Jacob M van Laar

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Jürgen Wollenhaupt

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Herbert Kellner

12

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Jacqueline Paramarta

13

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Jiawei Wei

14

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Arndt Brachat

15

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Stephan Bek

16

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Didier Laurent

17

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Yali Li

18

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Ying A Wang

19

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Arthur P Bertolino

20

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Sandro Gsteiger

21

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Andrew M Wright

22

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Wolfgang Hueber

23

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

language of work or name

0 references

publication date

13 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

382

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

9906

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

1705-1713

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Spondyloarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Summarizing historical information on controls in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961134-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)61134-4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24035250

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46911236&oldid=2137610125"